166 related articles for article (PubMed ID: 2979764)
41. Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta.
Borden EC; Sidky YA; Hatcher JF; Bryan GT
Cancer Res; 1988 May; 48(9):2329-34. PubMed ID: 3356000
[TBL] [Abstract][Full Text] [Related]
42. [Role of intracellular pH in the development of resistance of leukemic cells to antineoplastic drugs].
Shestova OL; Ogloblina TA; Litinskaia LL
Eksp Onkol; 1990; 12(3):61-2. PubMed ID: 2344828
[TBL] [Abstract][Full Text] [Related]
43. Collateral sensitivity to cross-linking agents exhibited by cultured L1210 cells resistant to oxazaphosphorines.
Sladek NE; Low JE; Landkamer GJ
Cancer Res; 1985 Feb; 45(2):625-9. PubMed ID: 3967238
[TBL] [Abstract][Full Text] [Related]
44. Differential sensitivity to mitomycin C between human RSa cell line and its derivative UVr-1.
Hiwasa T; Chen Z; Nomura J; Yamamori H; Tashiro T; Nakajima N; Suzuki N
Anticancer Res; 1999; 19(5B):3915-20. PubMed ID: 10628331
[TBL] [Abstract][Full Text] [Related]
45. [Study for modifying activity of solvents on antitumor activity of paclitaxel].
Fujimoto S
Gan To Kagaku Ryoho; 1994 Apr; 21(5):665-70. PubMed ID: 7908793
[TBL] [Abstract][Full Text] [Related]
46. Restoration of sensitivity to oxazaphosphorines by inhibitors of aldehyde dehydrogenase activity in cultured oxazaphosphorine-resistant L1210 and cross-linking agent-resistant P388 cell lines.
Sladek NE; Landkamer GJ
Cancer Res; 1985 Apr; 45(4):1549-55. PubMed ID: 3978623
[TBL] [Abstract][Full Text] [Related]
47. Mitomycin C combination therapy against murine tumor systems. Effectiveness with cyclophosphamide and methotrexate.
Mabel JA; Wodinsky I
Cancer; 1983 Feb; 51(4):600-5. PubMed ID: 6401590
[TBL] [Abstract][Full Text] [Related]
48. Antitumor activity and toxicity in animals of BMY-25282, a new mitomycin derivative.
Bradner WT; Rose WC; Schurig JE; Florczyk AP; Huftalen JB; Catino JJ
Cancer Res; 1985 Dec; 45(12 Pt 1):6475-81. PubMed ID: 3933826
[TBL] [Abstract][Full Text] [Related]
49. Resistance to anthrapyrazoles and anthracyclines in multidrug-resistant P388 murine leukemia cells: reversal by calcium blockers and calmodulin antagonists.
Klohs WD; Steinkampf RW; Havlick MJ; Jackson RC
Cancer Res; 1986 Sep; 46(9):4352-6. PubMed ID: 3460695
[TBL] [Abstract][Full Text] [Related]
50. Antitumor activity of a derivative of mitomycin, 7-N-[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]mitomycin C (KW-2149), against murine and human tumors and a mitomycin C-resistant tumor in vitro and in vivo.
Tsuruo T; Sudo Y; Asami N; Inaba M; Morimoto M
Cancer Chemother Pharmacol; 1990; 27(2):89-93. PubMed ID: 2123421
[TBL] [Abstract][Full Text] [Related]
51. Development and cross-resistance characteristics of a subline of P388 leukemia resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide.
Johnson RK; Howard WS
Eur J Cancer Clin Oncol; 1982 May; 18(5):479-87. PubMed ID: 6956514
[No Abstract] [Full Text] [Related]
52. Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia.
Waud WR; Harrison SD; Gilbert KS; Laster WR; Griswold DP
Cancer Chemother Pharmacol; 1991; 27(6):456-63. PubMed ID: 1849465
[TBL] [Abstract][Full Text] [Related]
53. Techniques to reverse or circumvent drug-resistance in vitro.
Kuwano M; Nakagawa M; Shiraishi N; Yamaguchi T; Kikuchi J; Akiyama S
Prog Clin Biol Res; 1986; 223():163-71. PubMed ID: 3809198
[TBL] [Abstract][Full Text] [Related]
54. Modulation of mitomycin C resistance by glutathione transferase inhibitor ethacrynic acid.
Singh SV; Xu BH; Maurya AK; Mian AM
Biochim Biophys Acta; 1992 Nov; 1137(3):257-63. PubMed ID: 1445927
[TBL] [Abstract][Full Text] [Related]
55. In vivo properties of the conjugates of mitomycin C with estradiol benzoate and estradiol: pharmacokinetics and antitumor characteristics against P388 leukemia and sarcoma 180.
Ishiki N; Onishi H; Machida Y
Biol Pharm Bull; 1998 Nov; 21(11):1180-6. PubMed ID: 9853409
[TBL] [Abstract][Full Text] [Related]
56. Comparison of uptake of mitomycin C and KW-2149 by murine P388 leukemia cells sensitive or resistant to mitomycin C.
Kobayashi E; Okabe M; Kono M; Arai H; Kasai M; Gomi K; Lee JH; Inaba M; Tsuruo T
Cancer Chemother Pharmacol; 1993; 32(1):20-4. PubMed ID: 8096440
[TBL] [Abstract][Full Text] [Related]
57. Decreased phorbol ester receptor and protein kinase C in P388 murine leukemic cells resistant to etoposide.
Ido M; Sato K; Sakurai M; Inagaki M; Saitoh M; Watanabe M; Hidaka H
Cancer Res; 1987 Jul; 47(13):3460-3. PubMed ID: 3581082
[TBL] [Abstract][Full Text] [Related]
58. [Biochemical mechanisms of resistance to a new antineoplastic agent amin(cyclopeptidylamin)-S-(-)-malatoplatinum (II) (cycloplatam)].
Dederer LIu; Lankin VZ; Konovalova AL; Gorbacheva LB
Biokhimiia; 1995 Apr; 60(4):602-9. PubMed ID: 7779982
[TBL] [Abstract][Full Text] [Related]
59. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil.
Tsuruo T; Iida H; Tsukagoshi S; Sakurai Y
Cancer Res; 1981 May; 41(5):1967-72. PubMed ID: 7214365
[TBL] [Abstract][Full Text] [Related]
60. Calmodulin inhibitor trifluoperazine selectively enhances cytotoxic effects of strong vs weak DNA binding antitumor drugs in doxorubicin-resistant P388 mouse leukemia cells.
Ganapathi R; Grabowski D; Schmidt H; Seshadri R; Israel M
Biochem Biophys Res Commun; 1985 Sep; 131(2):912-9. PubMed ID: 2932108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
